Pure Global
NCT05022875

Effectiveness of The Health Care CEO App for T1D

Effectiveness of the 'Healthcare CEO' App for Type 1 Diabetes Patients Transitioning From Adolescence to Early Adulthood: Protocol for a Randomized Controlled Trial
Chang Gung University·ClinicalTrials.gov·device·Device trialRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Type 1 Diabetes Mellitus
Drug/Device/Intervention
Healthcare CEO app- for experimental app intervention
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Chang Gung University
Location
Taoyuan, Taiwan
Timeline & enrollment
Phase
N/A
Start date
Apr 23, 2021
End date
Jul 31, 2022
Enrollment
96 participants
Primary outcome

Change in HbA1c,Change in % with HbA1c 7.0%,Change in Hyperglycemic Events,Change in Hypoglycemic Events

Summary

The present study aims to evaluate the intervention effectiveness of the Healthcare Chief
 Executive Officer mobile application(Healthcare CEO app) in patients with type 1 diabetes
 transitioning from adolescence to early adulthood.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05022875
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT05022875 through Pure Global AI's free database. This phase not specified trial is sponsored by Chang Gung University and is currently Recruiting. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 96 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.